Improving the therapeutic index in myeloma.

摘要

In this issue of Blood, Bringhen and colleagues report on the efficacy and safety of once-weekly bortezomib in multiple myeloma (MM) patients. The authors report on a post-hoc analysis which assessed the impact of schedule change on clinical outcomes as part of their randomized phase 3 trial, which compared the combination of bortezomib, melphalan, and prednisone with thalidomide followed by maintenance treatment with bortezomib and thalidomide, versus a current standard approach, namely bortezomib, melphalan, and prednisone.